One for the scientists again, I’m afraid. I’ve been reading In The Pipeline for a while now, which is a well-written chronicle of the life of a medicinal chemist plus other matters of interest in the pharmaceutical industry. He’s dealt with polonium posioning, a post on a new twist to RNA interference that makes a nice pair with one on Merck’s acquisition of Sirna, and something that I’ve laughed about before, the crap names of biotech and pharma companies. Recently the author has been made redundant, which is something I have in common with him; the company I work for went breasts-skyward a few months ago, but I have potential employment with a company that is spinning out from the wreckage. Of course, in contravention of the naming rules suggested in Lowe’s post, the new company’s name ends in an “X”; hopefully people won’t mind the cliche.
Another chemblog I’ve been keeping an eye on is Totally Medicinal, which is usually posts centred on recent publications in the chemistry literature, plus other synthesis highlights. It’s definitely a case of a good writing style rescuing what could be quite turgid subject matter; for example, in Feeling Aroused?, TM writes
In BMC (2007, 15, 142-159) Pfizer are riding to the rescue of the sufferers of FSAD – that’s Female Sexual Arousal Disorder. [Stop sniggering at the back there!]. Far be it for me to suggest that this is in fact a bullshit, totally made-up, non-disease. Nothing to do with the fact that loads of people will want to buy these pills and make them loads and loads of money, even if they are only intended and approved for use in a very small subset of patients with a specific aetiology. This is a serious disorder, which demands serious medical attention.
I am looking forward to seeing the spammers latching onto this as soon as a compound makes it to the market. And it’s rare to see a chemical series described as “a bit gash” in the literature.


